Overview of chemoradiation clinical trials for locally advanced non-small cell lung cancer in Japan

Pharmacology, Toxicology and Pharmaceutical Science

• Anticarcinogen 16%
• Carboplatin 50%
• Chemoradiation Therapy 83%
• Chemotherapy 100%
• Cisplatin 33%
• Clinical Trial 33%
• Docetaxel 16%
• Epidermal Growth Factor Receptor 16%
• Gefitinib 16%
• Gimeracil 16%
• Group Trial 16%
• Irinotecan 16%
• Lung Cancer 33%
• Maximum Tolerated Dose 16%
• Median Survival Time 16%
• Mitomycin 16%
• Non Small Cell Lung Cancer 66%
• Oteracil Potassium 16%
• Paclitaxel 33%
• Protein Tyrosine Kinase 16%
• Radiation 83%
• Survival 16%
• Survival Rate 16%
• Tegafur 16%
• Toxicity 33%
• Vindesine 16%